Epstein-Barr virus Latent Membrane Protein LMP1 reduces p53 protein levels independent of the PI3K-Akt pathway

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Husaini, Roslina ^a   Ahmad, Munirah ^a   Khoo, Alan Soo Beng ^a  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

Author keywords

Epstein Barr virus; Latent membrane protein; Nasopharyngeal carcinoma (NPC); p53 tumour suppressor gene; ubiquitination

Indexed keywords

HUMAN HERPESVIRUS 4;

EID: 83755196626     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-551     Document Type: Article

References (31)

1. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide (version 1.0). Ferlay J, IARC Press, Lyon Version 1.0 2001
2. Nasopharyngeal carcinoma: a delay in diagnosis. Prasad U, Pua KC, The Medical journal of Malaysia 2000 55 230 235 19839151
3. Nasopharyngeal Carcinoma Database. Pua KC, Khoo AS, Yap YY, Subramaniam SK, Ong CA, Gopala Krishnan G, Shahid H, The Medical journal of Malaysia 2008 63 Suppl C 59 62 19230249
4. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N, The New England journal of medicine 1995 333 693 698 10.1056/NEJM199509143331103 7637746
5. Epstein-Barr virus - increasing evidence of a link to carcinoma. Kieff E, The New England journal of medicine 1995 333 724 726 10.1056/ NEJM199509143331110 7637753
6. Immunohistochemical expression of Epstein-Barr virus-encoded latent membrane protein (LMP-1) in paraffin sections of EBV-associated nasopharyngeal carcinoma in Spanish patients. Vera-Sempere FJ, Burgos JS, Botella MS, Cordoba J, Gobernado M, Eur J Cancer B Oral Oncol 1996 32B 163 168 8762873
7. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Lin SY, Tsang NM, Kao SC, Hsieh YL, Chen YP, Tsai CS, Kuo TT, Hao SP, Chen IH, Hong JH, Head Neck 2001 23 194 200 10.1002/1097-0347(200103)23:3<194::AID-HED1018>3.0. CO;2-X 11428449
8. Epstein-Barr virus induces invasion and metastasis factors. Wakisaka N, Pagano JS, Anticancer Res 2003 23 2133 2138 12894587 (Pubitemid 36897173)
9. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, Rickinson AB, Nature 1991 349 612 614 10.1038/349612a0 1705663 (Pubitemid 21912115)
10. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A, Cell 1991 65 1107 1115 10.1016/0092-8674(91)90007-L 1648447 (Pubitemid 121001325)
11. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM, The Journal of biological chemistry 1992 267 24157 24160 1332946
12. Epstein-Barr virus in the pathogenesis of NPC. Raab-Traub N, Semin Cancer Biol 2002 12 431 441 10.1016/S1044579X0200086X 12450729 (Pubitemid 35370756)
13. WAF1, a potential mediator of p53 tumor suppression. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B, Cell 1993 75 817 825 10.1016/0092-8674(93)90500-P 8242752 (Pubitemid 23346378)
14. Participation of p53 protein in the cellular response to DNA damage. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW, Cancer research 1991 51 6304 6311 1933891
15. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M, Nature 1991 352 345 347 10.1038/352345a0 1852210 (Pubitemid 21912356)
16. The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, Gabrielli B, Oncogene 2004 23 1342 1353 10.1038/sj.onc.1207253 14716295 (Pubitemid 38406830)
17. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Wade M, Allday MJ, Mol Cell Biol 2000 20 1344 1360 10.1128/MCB.20.4.1344-1360.2000 10648620 (Pubitemid 30069255)
18. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Saridakis V, Sheng Y, Sarkari F, Holowaty MN, Shire K, Nguyen T, Zhang RG, Liao J, Lee W, Edwards AM, Mol Cell 2005 18 25 36 10.1016/j.molcel.2005.02.029 15808506 (Pubitemid 40444645)
19. Overexpression of p53 and neoplastic cell proliferation in undifferentiated nasopharyngeal carcinoma. Taweevisit M, Southeast Asian J Trop Med Public Health 2007 38 136 140 17539259
20. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Gulley ML, Burton MP, Allred DC, Nicholls JM, Amin MB, Ro JY, Schneider BG, Human pathology 1998 29 252 259 10.1016/S0046-8177(98) 90044-2 9496828 (Pubitemid 28123922)
21. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Porter MJ, Field JK, Lee JC, Leung SF, Lo D, Van Hasselt CA, Anticancer Res 1994 14 1357 1360 8067705 (Pubitemid 24264188)
22. p53 and nasopharyngeal carcinoma: a Malaysian study. Hoe SL, Lee ES, Khoo ASB, Peh SC, Pathology 2009 41 561 565 10.1080/00313020903071504 19900105
23. Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. Liu MT, Chang YT, Chen SC, Chuang YC, Chen YR, Lin CS, Chen JY, Oncogene 2005 24 2635 2646 10.1038/sj.onc.1208319 15829976 (Pubitemid 40593091)
24. Latent membrane protein 1 of Epstein-Barr virus regulates p53 phosphorylation through MAP kinases. Li L, Guo L, Tao Y, Zhou S, Wang Z, Luo W, Hu D, Li Z, Xiao L, Tang M, Cancer letters 2007 255 219 231 10.1016/j.canlet. 2007.04.014 17582679 (Pubitemid 47271954)
25. The activation of p53 mediated by Epstein-Barr virus latent membrane protein 1 in SV40 large T-antigen transformed cells. Li L, Zhou S, Chen X, Guo L, Li Z, Hu D, Luo X, Ma X, Tang M, Yi W, et al. FEBS Lett 2008 582 755 762 10.1016/j.febslet.2008.01.031 18242176
26. Mdm2 promotes the rapid degradation of p53. Haupt Y, Maya R, Kazaz A, Oren M, Nature 1997 387 296 299 10.1038/387296a0 9153395 (Pubitemid 27220766)
27. Regulation of p53 stability by Mdm2. Kubbutat MH, Jones SN, Vousden KH, Nature 1997 387 299 303 10.1038/387299a0 9153396 (Pubitemid 27220767)
28. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Midgley CA, Lane DP, Oncogene 1997 15 1179 1189 10.1038/sj.onc.1201459 9294611 (Pubitemid 27429621)
29. Mdm2 association with p53 targets its ubiquitination. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z, Oncogene 1998 17 2543 2547 10.1038/sj.onc.1202200 9824166 (Pubitemid 28544725)
30. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y, The Journal of biological chemistry 2002 277 21843 21850 10.1074/jbc.M109745200 11923280 (Pubitemid 34952337)
31. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W, Science New York, NY 2003 302 1972 1975 10.1126/science.1091362 14671306 (Pubitemid 37523506)